Israeli medical technology firm to establish US headquarters and create 100 positions in Manatee County.

Key Information

• Company: Ossio, an Israel-based medtech company
• Location: New U.S. headquarters in Palmetto, Manatee County, Florida
• Facility Size: 30,000 square feet for manufacturing and training
• Job Creation: Approximately 100 jobs over the next five years
• Production Start Date: Spring 2026
• Investment: Over $27 million raised in equity funding
• Market Value: The orthopedic fixation market is valued at over $15 billion

Ossio, a burgeoning Israeli medtech firm, is set to establish its U.S. headquarters in Manatee County.

The company is currently converting a 30,000 square foot leased space in Palmetto into a manufacturing plant and a center for surgeon training.

Ossio specializes in metal-free fixation implants created from a unique material that supports bone regeneration. These implants are crucial for setting and stabilizing bones, traditionally involving screws, plates, and pins.

Ossio’s expansion into the U.S. comes in response to a growing demand for its products, as indicated by CEO Brian Verrier. “The U.S. is our primary focus, and the business has grown significantly over the last 5 years based on exceptional demand from U.S. orthopedic surgeons,” Verrier shared in an email to the Business Observer.

Since launching its first product in 2019, over 60,000 Ossio implants have been utilized in U.S. orthopedic treatments by September 2025. “Our move to implement U.S. manufacturing addresses our capacity needs and brings us closer to our customer base,” he stated.

Ossio currently manages its development and manufacturing out of Caesarea, Israel, with its commercial headquarters located in Boston.

Verrier explains that products transitioning from R&D into large-scale manufacturing will stay in Israel, while high-volume offerings will be produced in Palmetto. This strategy ensures continuity of operations if one site encounters disruptions.

The company’s plans to boost production have been deliberate. In December, Ossio secured over $27 million in equity funding to accelerate its commercial initiatives, including the new site in north Manatee County.

‘Attractive Combination’

The decision to locate in Florida International Tradeport, a two million square foot industrial park near Interstate 75, was influenced by several factors. “Florida fosters a culture of innovation in health care and life sciences,” Verrier noted, emphasizing the Tampa region’s appeal for medical technology firms owing to its technical talent and economic incentives.

The new facility is expected to generate around 100 jobs within the next five years. The company plans to start hiring for various roles this fall, with production of its metal-free implants slated to commence in spring 2026.

Verrier also highlighted Ossio’s commitment to education, stating that the company trains between 150 to 200 surgeons each year, collaborating to refine how their technology enhances surgical outcomes across numerous clinical scenarios.

Florida Secretary of Commerce J. Alex Kelly remarked that Ossio’s addition to the region’s health technology sector would significantly bolster Florida’s life sciences employment and innovation metrics.

Proprietary Tech

Ossio’s growing product demand stems from a rising preference among patients and surgeons to avoid complications associated with traditional metal implants.

As outlined on its website, metal implants can lead to pain, allergic reactions, and the weakening of surrounding bones; notably, one in four individuals has their metal implants removed in a subsequent surgery.

“While orthopedics has experienced substantial innovation, metal fixation has persisted as the standard since before the Civil War,” Verrier stated.

He added that Ossio has addressed a significant materials and engineering challenge, producing implants with comparable mechanical strength to metal, while offering superior biocompatibility.

The proprietary polymeric mineral fiber matrix utilized in Ossio’s implants facilitates rapid bone in-growth and regeneration. This innovation allows orthopedic surgeons to restore stability and mobility without leaving behind permanent materials.

Looking ahead, the company aims to further develop applications for its implants across all major orthopedic segments, targeting the $15 billion orthopedic fixation market.